Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AKP-201
- Development stage
- Unknown
- Lead developer
- Asahi Kasei Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AKP-201 is an orally bioavailable, selective P2X3 receptor antagonist currently under development by Asahi Kasei Pharma. It is primarily being investigated for the treatment of refractory or unexplained chronic cough (RCC/UCC). The drug's mechanism involves the inhibition of P2X3 receptors, which are ATP-gated ion channels located on sensory nerve fibers (C-fibers) in the airways. In chronic cough conditions, excessive ATP release and subsequent P2X3 receptor activation lead to neuronal hypersensitivity and an exaggerated cough reflex. By antagonizing these receptors, AKP-201 aims to reduce the hypersensitivity of the cough reflex arc and decrease cough frequency.
02
Targets
P2X3 (P2X purinoceptor 3)
Beyond the preview
Go deeper on AKP-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AKP-201.